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Effect of efflux pump inhibition 
on Pseudomonas aeruginosa 
transcriptome and virulence
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Efflux pumps of the resistance-nodulation-cell-division (RND) family increase antibiotic resistance in 
many bacterial pathogens, representing candidate targets for the development of antibiotic adjuvants. 
RND pumps have also been proposed to contribute to bacterial infection, implying that efflux pump 
inhibitors (EPIs) could also act as anti-virulence drugs. Nevertheless, EPIs are usually investigated only 
for their properties as antibiotic adjuvants, while their potential anti-virulence activity is seldom taken 
into account. In this study it is shown that RND efflux pumps contribute to Pseudomonas aeruginosa 
PAO1 pathogenicity in an insect model of infection, and that the well-characterized EPI Phe-Arg-β-
naphthylamide (PAβN) is able to reduce in vivo virulence of the P. aeruginosa PAO1 laboratory strain, 
as well as of clinical isolates. The production of quorum sensing (QS) molecules and of QS-dependent 
virulence phenotypes is differentially affected by PAβN, depending on the strain. Transcriptomic and 
phenotypic analyses showed that the protection exerted by PAβN from P. aeruginosa PAO1 infection 
in vivo correlates with the down-regulation of key virulence genes (e.g. genes involved in iron and 
phosphate starvation). Since PAβN impacts P. aeruginosa virulence, anti-virulence properties of EPIs are 
worthy to be explored, taking into account possible strain-specificity of their activity.
Introduction of any antibiotic in the clinical practice invariably results in ensuing resistance. The indiscriminate 
use of antibiotics and the increasing emergence of antibiotic resistance has drained the research in this field, 
resulting in a discovery rate of new antibiotics unable to compensate the escalation of antibiotic resistance in 
common pathogens1, 2.
The serious economic and health problems caused by multi-drug resistant (MDR) pathogens have fostered 
research not only into new antibiotics but also into novel adjuvants1, 2. Different from conventional antibiotics, 
adjuvants share the distinctive feature of targeting bacterial factors not essential for growth, such as virulence 
determinants (e.g. toxins, adhesins and tissue-degrading enzymes) or antibiotic resistance determinants (e.g. 
efflux pumps, antibiotic inactivating enzymes). Such treatments are aimed at facilitating host immune response 
and/or antibiotic action in clearing the infection. As to anti-virulence drugs, they are predicted to exert a low 
selective pressure for the emergence of resistant strains, since they do not directly inhibit bacterial growth2–4.
The active efflux of antibiotics via efflux pumps contributes to the bacterial MDR phenotype, and the develop-
ment of efflux pump inhibitors (EPIs) is considered a promising adjuvant strategy2, 5–7. Efflux pumps are catego-
rized into different families on the basis of the amino acid sequence, the energy source required to drive antibiotic 
export, and the substrate specificity. The resistance-nodulation-cell-division (RND) family of efflux pumps is con-
sidered a viable target for the development of drugs aimed at increasing bacterial susceptibility to antibiotics, due 
to their prominent contribution to the MDR phenotype and to the absence of human homologues2, 5–7. Notably, 
evidence is emerging that some RND transporters are also involved in the efflux of bacterial factors important 
for virulence8, 9. These preliminary observations suggest that EPIs targeting RND efflux pumps could also affect 
bacterial virulence, in addition to facilitating antibiotic activity.
Pseudomonas aeruginosa is one of the most dreaded opportunistic pathogens, representing a paradigm of 
Gram-negative MDR “superbug” for which effective therapeutic options are limited. The ability of P. aeruginosa to 
cause a wide range of infections in humans is due to its capacity to produce a large repertoire of virulence factors 
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and, ultimately, respond and adapt to harsh conditions as those imposed by the host immune response and anti-
biotic exposure1. The pathogenic potential of P. aeruginosa relies on the coordinated expression of a large array 
of virulence factors, the majority of which are positively controlled by quorum sensing (QS)10. The three main P. 
aeruginosa QS systems are based on the production of specific signal molecules, namely the N-acyl-homoserine 
lactones (AHLs) N-3-oxododecanoyl-homoserine lactone (3OC12-HSL) and N-butanoyl-homoserine lactone 
(C4-HSL), and the 2-alkyl-4-quinolones (AQs) 2-heptyl-4-hydroxyquinoline (HHQ) and 2-heptyl-3-hydroxy-
4-quinolone (PQS). These systems are hierarchically organized, since 3OC12-HSL is required for optimal pro-
duction of all QS signals10. Moreover, the P. aeruginosa genome is predicted to encode multiple RND efflux 
pumps, four of which are of clinical importance for MDR, namely MexAB-OprM, MexCD-OprJ, MexEF-OprN 
and MexXY-OprM, and are frequently found to be up-regulated in clinical isolates11.
The MexAB-OprM is considered as the most important RND efflux pump for P. aeruginosa, since it is con-
stitutively expressed and provides intrinsic resistance to a broad spectrum of antibiotics11. The emergence of P. 
aeruginosa MexAB-OprM over-expressing mutants in a rat model of acute pneumonia suggests that this efflux 
pump confers a selective advantage in vivo, also in the absence of antibiotic treatment12. Moreover, P. aerugi-
nosa lacking the MexAB-OprM efflux pump could not invade Madin-Darby canine kidney (MDCK) epithelial 
cells, and invasion could be restored by supplementation with culture supernatants obtained from MDCK cells 
infected with wild type P. aeruginosa13. In addition, it was reported that MexAB-OprM participates in the efflux 
of 3OC12-HSL14, 15 and that MexEF-OprN and MexGHI-OprM could be involved in transport of some AQs16, 17. 
All these data argue for a role of MexAB-OprM and other P. aeruginosa RND efflux pumps in the export of viru-
lence determinants contributing to invasiveness and infection.
Phe-Arg-β-naphthylamide (PAβN, also named MC-207,110) is the most active and best studied inhibitor of 
P. aeruginosa RND efflux pumps. It was discovered in a screen for adjuvants of the fluoroquinolone levofloxa-
cin, carried out in a P. aeruginosa strain that over-expressed MexAB-OprM, though this EPI was also found to 
be active against other RND pumps like MexCD-OprJ and MexEF-OprN18, 19, indicating that PAβN is a broad 
spectrum EPI2, 5. In agreement with the results obtained with MexAB-OprM-deficient cells13, it has been shown 
that PAβN reduces the invasiveness of P. aeruginosa in MDCK cells20, suggesting that this compound could also 
inhibit some P. aeruginosa virulence traits. Indeed, PAβN decreases the production of the QS signals 3OC12-HSL 
and C4-HSL, and of some QS-dependent virulence phenotypes in P. aeruginosa MDR isolates from urinary and 
wound infections21. Beside its role as EPI, it has been reported that PAβN can affect P. aeruginosa membrane 
permeability, and consequently bacterial growth, when used beyond certain concentrations (~50–200 µM)19, 22. 
This side effect is particularly relevant in efflux pumps deficient genetic backgrounds19, 22, and complicates the 
understanding of the mechanism of action of PAβN as an EPI and as a virulence inhibitor.
This study is aimed at investigating the effect of PAβN on the general physiology and virulence of the widely 
studied model strain P. aeruginosa PAO1, by performing microarray analysis and Galleria mellonella infection 
experiments. We also provide evidence that PAβN affects to different extent virulence-related phenotypes in P. 
aeruginosa clinical isolates.
Results and Discussion
pAβN treatment extensively affects the P. aeruginosa transcriptome. A major requirement for 
anti-virulence drugs is their ability to inhibit virulence traits without affecting cell viability3, 4. Hence, PAβN con-
centrations not affecting the growth rate of P. aeruginosa (i.e. ≤50 µM; Fig. S1) were used throughout this study.
The transcriptional profiles of P. aeruginosa PAO1 grown to an A600 of 2.5 in LB in the presence or in the 
absence of 27 µM PAβN were compared by means of high-density oligonucleotide microarrays, by using 
Affimetrix GeneChip® for P. aeruginosa PAO1. Following statistical validation of the dataset, only genes with 
a fold change >2 and a p-value <0.05 were considered for further analysis. Selected genes significantly up- or 
down-regulated by PAβN are listed in Tables 1 and 2, respectively (the complete gene list is given in Table S1, 
Supporting Information).
The transcription of 108 genes was significantly affected by PAβN (Table S1), corresponding to about 1.9% of 
P. aeruginosa PAO1 genes23. Of these, 39 genes were up-regulated and 69 genes were down-regulated in the pres-
ence of PAβN (Table S1). Among the 39 genes up-regulated by PAβN, the most represented categories comprise 
genes involved in nitrogen metabolism (nir, nor and nos genes; 33.3% of up-regulated genes) and in biosynthe-
sis of phenazines (phz genes; 10.2% of up-regulated genes) (Tables 1 and S1). Phenazines constitute a group of 
nitrogen-containing heterocyclic compounds, including the virulence factor pyocyanin24.
Among the 69 down-regulated genes, 46 genes (66.7%) were previously reported to be repressed by iron25. 
These include almost all the genes involved in the biosynthesis, uptake and regulatory response to the sidero-
phores pyoverdine and pyochelin, including the pvdS sigma factor gene, which also activates the expression 
of prpL protease and toxA toxin genes (Tables 2 and S1). Moreover, metabolic and virulence genes previously 
shown to be induced in response to iron starvation were down-regulated by PAβN, including fumarate hydratase 
(fumC1), superoxide dismutase (sodM) and protease (aprX) genes (Table 2). The negative effect exerted by PAβN 
on the iron-starvation response pathway correlates with previous studies showing that PAβN synergizes with iron 
chelators in reducing the growth rate and biofilm formation of P. aeruginosa26. Moreover, PAβN treatment caused 
down-regulation of genes repressed by phosphate availability, including pho, pst and pnh genes27 (Tables 2 and 
S1). Overall, the expression of many genes important for P. aeruginosa pathogenicity, such as pvdS, phoB, pstS and 
vreR25–30, was strongly repressed by PAβN (Table 2).
The differential expression of selected genes identified as PAβN-controlled was validated by quantitative 
reverse transcription PCR (qRT-PCR) analysis performed on P. aeruginosa cultures grown under the same con-
ditions as those used for the microarray experiment. The qRT-PCR results matched the microarray data, since the 
mRNA level of the norB and qteE genes increased in the presence of 27 µM PAβN, while the mRNA level of the 
pvdQ, aprX, fumC1, pvdS and sodM genes decreased in the same conditions (Fig. 1A).
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Despite the concentration of PAβN used in this experiment (27 µM) is not expected to destabilize the cell 
membrane of wild type PAO1, the possibility that this EPI controls some of the identified genes via membrane 
perturbation rather than efflux pump inhibition cannot be ruled out. However, the specificity of PAβN effect as 
an EPI in our settings is supported by the observation that only 2 out of the 108 PAβN-regulated genes (i.e. phzF1 
and PA4139; Table S1) were identified in a previous microarray analysis performed with sub-MIC concentration 
of the membrane destabilizing peptide polymyxin E (colistin)31 (Table S1). Furthermore, none of the genes whose 
expression was altered upon exposure to sub-MIC concentration of polymyxin B32 were affected by PAβN.
Additional qRT-PCR analyses were also performed to further support the primary role of PAβN as an EPI. 
Since previous reports showed that 1 mM Mg2+ completely abolished the permeabilizing effect exerted by PAβN 
on bacterial membranes19, 33, the effect of PAβN on the mRNA level of qteE, pvdS and sodM was compared in the 
absence and in the presence of 1 mM MgSO4. The expression of the same genes was also evaluated in a P. aerugi-
nosa efflux-deficient mutant (PAO1-KP Δefflux) carrying deletions in genes encoding the four major RND efflux 
pumps of this bacterium, namely MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM34 (Table S2). 
Since this mutant was not generated in our laboratory, and it is well known that PAO1 strains maintained in dif-
ferent laboratories disclose genotype variability35, strain PAO1-KP Δefflux was compared with its isogenic wild 
type strain PAO1-KP34.
This experiment revealed that 27 µM PAβN increases the mRNA level of qteE and decreases the mRNA level 
of pvdS and sodM irrespective of the presence or the absence of MgSO4, both in PAO1 (Fig. 1B) and in PAO1-KP 
(Fig. 1C). Notably, the fold change in the mRNA level of the tested genes was similar in PAO1-KP supplemented 
with PAβN and in PAO1-KP Δefflux relative to untreated PAO1-KP (Fig. 1C), supporting the conclusion that 
the alteration in gene expression caused by PAβN relies on its ability to inhibit efflux pumps, rather than on its 
membrane permeabilizing effect. This is in line with previous reports suggesting that PAβN has a strong activ-
ity as an efflux pump inhibitor and a weak, concentration-dependent activity in destabilizing the cell envelope, 
both in P. aeruginosa and in Escherichia coli19, 33. Unfortunately, the well-known toxic effect of PAβN to efflux 
pumps-deficient P. aeruginosa cells2, 19 does not allow to investigate the effect of PAβN on the PAO1-KP Δefflux 
strain.
Overall, these data indicate that the PAβN-dependent inhibition of efflux pumps has a profound impact on 
the P. aeruginosa transcriptome.
PA numbera Gene namea Fold changeb Product namea
PA0509* nirN 2.27 NirN
PA0510* nirE 2.33 NirE
PA0511* nirJ 2.23 hemed1 biosynthesis protein NirJ
PA0514* nirL 2.3 hemed1 biosynthesis protein NirL
PA0516* nirF 2.3 hemed1 biosynthesis protein NirF
PA0517* nirC 3.53 probable c-type cytochrome precursor
PA0518* nirM 3.32 cytochrome c551 precursor
PA0519* nirS 4.48 nitrite reductase precursor
PA0523* norC 2.87 nitric-oxide reductase subunit C
PA0524* norB 5.51 nitric-oxide reductase subunit B
PA0525* norD 2.19 probable denitrification protein NorD
PA1901§ phzC1/C2 2.24 phenazine biosynthesis protein PhzC
PA1902§ phzD1/D2 2.26 phenazine biosynthesis protein PhzD
PA1903§ phzE1/E2 2.22 phenazine biosynthesis protein PhzE
PA1904§ phzF1/F2 2.11 probable phenazine biosynthesis protein
PA2593 qteE 2.06 quorum threshold expression element, QteE
PA3392* nosZ 2.16 nitrous-oxide reductase precursor
PA4810* fdnI 2.22 nitrate-inducible formate dehydrogenase, γ subunit
Table 1. Selected genes whose transcription is up-regulated by PAßN. aPA number, gene name and product 
name are from the Pseudomonas Genome Database23. Genes previously reported as controlled by 3OC12-HSL 
are in bold characters36–38. *Genes involved in nitrogen metabolism; §Genes involved in phenazines biosynthesis. 
bFold change in gene expression in P. aeruginosa PAO1 grown in LB supplemented with 27 µM PAßN with 
respect to the same strain grown in LB.
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pAβN treatment affects P. aeruginosa virulence-related phenotypes. The expression of the genes 
involved in 3OC12-HSL and C4-HSL synthesis and reception (i.e. lasI-lasR, and rhlI-rhlR, respectively) and of the 
vast majority of genes known to be controlled by these QS signal molecules36–38 was not inhibited by PAβN in the 
microarray analysis (Table S1). This result and the positive effect exerted by PAβN on the expression of pyocyanin 
biosynthetic genes was not expected, since PAβN was previously shown to negatively affect the transcription of the 
las and rhl QS genes and the expression of phenotypes controlled by QS (i.e. pyocyanin, proteases and elastase pro-
duction) in P. aeruginosa strains isolated from urinary tract and wound infections21. To clarify this issue, we meas-
ured the level of QS signals (i.e. 3OC12-HSL, C4-HSL and HHQ/PQS) and of the above-mentioned QS-dependent 
virulence factors in supernatants collected from P. aeruginosa PAO1 cultures in LB supplemented with increasing 
concentrations of PAβN (experimental details are given in Materials and Methods). Results showed that the pro-
duction of 3OC12-HSL is significantly increased in the presence of PAβN concentrations ≥9 µM (Fig. 2A), while 
C4-HSL and HHQ/PQS production was not affected even at the maximum PAβN concentration tested (50 µM; 
Fig. 2A). The observation that PAβN increases 3OC12-HSL production both in PAO1 and in PAO1-KP also in the 
presence of 1 mM MgSO4, and that 3OC12-HSL levels are higher in the supernatant of PAO1-KP Δefflux relative to 
PA 
numbera
Gene 
namea Fold changeb Product namea
PA0672∫ hemO −4.81 hemeoxygenase
PA0676∫ vreR −4.85 sigma factor regulator, VreR
PA0707 toxR −2.12 transcriptional regulator ToxR
PA1245 aprX −3.44 AprX
PA1912∫ femI −2.35 ECF sigma factor, FemI
PA2385∫ pvdQ −2.98 3OC12-homoserine lactone acylasePvdQ
PA2386∫ pvdA −3.97 L-ornithine N5-oxygenase
PA2394∫ pvdN −2.85 PvdN
PA2395∫ pvdO −2.32 PvdO
PA2396∫ pvdF −3.22 pyoverdinesynthetase F
PA2397∫ pvdE −3.16 pyoverdine biosynthesis protein PvdE
PA2398∫ fpvA −2.03 ferripyoverdine receptor
PA2399∫ pvdD −3.32 pyoverdinesynthetase D
PA2400∫ pvdJ −3.36 PvdJ
PA2413∫ pvdH −3.58 l-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase
PA2424∫ pvdL −3.73 PvdL
PA2425∫ pvdG −2.58 PvdG
PA2426∫ pvdS −10.48 sigma factor PvdS
PA2570 lecA −2.42 LecA
PA3377◊ phnJ −21.1 conserved hypothetical protein
PA3407∫ hasAp −4.15 heme acquisition protein HasAp
PA3530∫ bfd −2.54 bacterioferritin-associated ferredoxinBfd
PA4221∫ fptA −2.52 Fe(III)-pyochelin outer membrane receptor precursor
PA4224∫ pchG −2.05 pyochelin biosynthetic protein PchG
PA4225∫ pchF −2.26 pyochelinsynthetase
PA4226∫ pchE −2.06 dihydroaeruginoic acid synthetase
PA4228∫ pchD −2.09 pyochelin biosynthesis protein PchD
PA4230∫ pchB −2.69 salicylate biosynthesis protein PchB
PA4468 sodM −11.65 superoxide dismutase
PA4470 fumC1 −8.96 fumaratehydratase
PA4708∫ phuT −3.17 heme-transport protein, PhuT
PA4709∫ phuS −3.37 PhuS
PA4710∫ phuR −4.65 heme/hemoglobin uptake outer membrane receptor PhuR
PA5360◊ phoB −15.28 two-component response regulator PhoB
PA5365◊ phoU −9.4 phosphate uptake regulatory protein PhoU
PA5366◊ pstB −14.02 ATP-binding component of ABC phosphate transporter
PA5367◊ pstA −14.17 membrane protein component of ABC phosphate transporter
PA5369◊ pstS −23.49 periplasmic phosphate-binding protein, PstS
Table 2. Selected genes whose transcription is down-regulated by PAßN. aPA number, gene name and product 
name are from the Pseudomonas GenomeDatabase23. Genes previously reported as controlled by 3OC12-HSL 
are in bold characters36–38. ∫Genes previously reported to be controlled by iron starvation25; ◊Genes previously 
reported to be controlled by phosphate starvation27. bFold change in gene expression in P. aeruginosa PAO1 
grown in LB supplemented with 27 µM PAßN with respect to the same strain grown in LB.
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the supernatant of PAO1-KP (Fig. 2B) indicates that the effect of PAβN on 3OC12-HSL can be ascribed to the inhi-
bition of efflux pumps, rather than to membrane perturbation. Further experiments carried out with transcriptional 
fusions confirmed that PAβΝ did not affect lasI and lasR promoter activity in PAO1 (Fig. S2), in agreement with 
the microarray data. Hence, the positive effect exerted by PAβΝ on 3OC12-HSL production in P. aeruginosa does 
not appear to occur at the transcriptional level. Interestingly, PAβΝ reduced the transcription of pvdQ (Fig. 1 and 
Table 2), a gene coding for the PvdQ acylase, an enzyme responsible for 3OC12-HSL degradation39. Therefore, the 
increase in 3OC12-HSL level caused by PAβΝ could be due, at least in part, to a decreased degradation of this signal 
molecule as a consequence of pvdQ down-regulation. In addition, PAβΝ enhanced the transcription of qteE (Fig. 1 
and Table 1), a gene coding for a protein that hampers the activity of the 3OC12-HSL-receptor protein LasR40. The 
enhanced expression of QteE in PAβΝ-treated cells may result in reduced levels of active LasR, thus counterbalanc-
ing the effect of increased 3OC12-HSL levels on the transcription of LasR-dependent genes.
Figure 1. Validation of the microarray data by qRT-PCR. mRNA levels of the indicated genes quantified by 
qRT-PCR in: (A) The P. aeruginosa PAO1 strain grown to an A600 of 2.5 in LB supplemented with 27 µM PAßN, 
relative to the same strain grown in LB (grey bars), in comparison with microarray data for the same genes 
(white bars); (B) The P. aeruginosa PAO1 strain grown to an A600 of 2.5 in LB supplemented with 27 µM PAßN 
(white bars), with 1 mM MgSO4 (light-grey bars), or with 27 µM PAßN plus 1 mM MgSO4 (dark-grey bars) 
relative to the same strain grown in LB; (C) The P. aeruginosa PAO1-KP strain grown to an A600 of 2.5 in LB 
supplemented with 27 µM PAßN (white bars), with 1 mM MgSO4 (light-grey bars), or with 27 µM PAßN plus 
1 mM MgSO4 (dark-grey bars), and the P. aeruginosa PAO1-KP ∆efflux strain grown to an A600 of 2.5 in LB 
(black bars), relative to the PAO-KP strain grown in LB. The average of two independent analyses performed on 
three technical replicates is shown with SD.
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As shown in Fig. 3A, pyocyanin production increased in the presence of PAβN concentrations ≥9 µM by 
comparison with the untreated control. Conversely, PAβN did not affect the production of proteases and elastase 
(Fig. 3A). These results are in agreement with the microarray data, showing that PAβN increases the transcrip-
tion of pyocyanin biosynthetic genes in PAO1, without affecting the mRNA level of proteases and elastase genes 
(Tables 1 and S1). Therefore, it can be argued that the positive effect exerted by PAβN on pyocyanin production 
in P. aeruginosa PAO1 is likely exerted via a QS-independent pathways controlling phenazines biosynthesis. The 
increase in pyocyanin levels caused by PAβN treatment was maintained in the presence of MgSO4 in both PAO1 
and PAO1-KP, although the absolute pyocyanin levels were lower in PAO1-KP than in PAO1 (Fig. 3B). Moreover, 
pyocyanin production in PAO1-KP Δefflux was significantly increased relative to PAO1-KP (Fig. 3B). These 
observations suggest that pyocyanin production is affected by PAβN via specific EPI activity. High sequence 
homology of pyocyanin biosynthetic operons phzA1-G1 and phzA2-G2 in PAO123 does not allow discriminating 
their mRNAs via microarray or qRT-PCR analyses. Therefore, transcriptional fusions between the PphzA1 or 
PphzA2 promoters and the luxCDABE operon41 were used to clarify the effect of PAβN on the pyocyanin biosyn-
thetic operons. As shown in Fig. 3C, PAβN increased the activity of the PphzA1 promoter, while it did not affect 
PphzA2. Also in this case, the effect of PAβN was not alleviated in the presence of MgSO4 (Fig. 3C).
Additional phenotypic analyses revealed that 50 µM PAβN caused a 8-fold and 2-fold reduction of twitch-
ing and swimming motility compared with the untreated control, respectively (Fig. 4A). Moreover, swarming 
motility was completely abrogated in the presence of 6.25 µM PAβN (Fig. 4B), in agreement with previous obser-
vations on P. aeruginosa clinical isolates21. A substantial decrease in swimming, twitching and swarming was 
also observed in PAO1-KP Δefflux relative to PAO1-KP (Fig. 4C), indicating that the effect of PAβΝ on these 
phenotypes is mainly dependent on efflux pumps inhibition. The negative effect exerted by PAβΝ on P. aerugi-
nosa motility seems to be unrelated to an altered expression of pili, flagella or rhamnolipids biosynthetic genes, 
as suggested by the microarray results (Table S1). However, motility is a pleiotropic and energetically demanding 
process, strongly affected by nutrients availability. In this context, the metabolic alteration caused by PAβΝ (e.g. 
up-regulation of nitrogen metabolism genes and down-regulation of iron-uptake genes; Tables 1 and S1) could 
explain the effect of this EPI on P. aeruginosa motility. Moreover, it is well documented that pvdQ is up-regulated 
in swarming cells, while its deletion abrogates swarming motility in P. aeruginosa42. Thus the PAβΝ-mediated 
reduction of pvdQ transcription (Fig. 1 and Table 1) correlates with the strong inhibitory effect exerted by this 
EPI on swarming motility.
Figure 2. Effect of PAβN on QS signal molecules production. (A) 3OC12-HSL (white bars), C4-HSL (light-grey 
bars) and HHQ/PQS (dark-grey bars) production in P. aeruginosa PAO1 stationary phase cultures grown in 
LB or in LB supplemented with PAßN at the concentrations indicated below the histogram. (B) 3OC12-HSL 
production in the indicated strains grown in LB (white bars), or in LB supplemented with 27 µM with PAßN 
(light-grey bars), with 1 mM MgSO4 (dark-grey bars), or with 27 µM PAßN plus 1 mM MgSO4 (black bars). The 
average of at least three independent experiments is reported with SD; statistical significance with respect to the 
untreated sample is indicated with one asterisk (p < 0.05).
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In summary, the effects of PAβΝ on P. aeruginosa PAO1 QS and virulence-related phenotypes are in agree-
ment with the microarray analysis, and confirm that this molecule increases 3OC12-HSL and pyocyanin levels 
via specific EPI activity, without affecting the production of other QS signal molecules and of the QS-controlled 
virulence factors elastase and proteases.
In vivo anti-virulence activity of PAβN. The above results show that PAβN (≤50 µM) inhibits P. 
aeruginosa PAO1 processes related to motility and acquisition of micronutrients (i.e. phosphate and iron), 
relevant for pathogenesis in several models of acute infection25, 27–30. On the other hand, in the PAO1 strain 
PAβN stimulates the production of both 3OC12-HSL and pyocyanin, both playing a positive role in P. aerug-
inosa virulence10, 28, 43–45.
Figure 3. Effect of PAβN on pyocyanin production. (A) Pyocyanin (white bars), proteases (light-grey bars) 
and elastase (dark-grey bars) production in P. aeruginosa PAO1 cultures grown in LB in the absence or in 
the presence of PAßN at the concentrations indicated below the histogram. (B) Pyocyanin production in the 
indicated strains grown in LB (white bars), or in LB supplemented with 27 µM PAßN (light-grey bars), with 
1 mM MgSO4 (dark-grey bars), or with 27 µM PAßN plus 1 mM MgSO4 (black bars). Pyocyanin production 
of strain PAO1 grown in LB is considered as 100%. (C) PphzA1 (white bars) and PphzA2 (grey bars) promoter 
activity measured in P. aeruginosa PAO1 cultures grown in LB or in LB supplemented with 27 µM PAßN, with 
1 mM MgSO4, or with 27 µM PAßN plus 1 mM MgSO4, as indicated below the histogram. The average of at least 
three independent experiments is reported with SD; statistical significance with respect to the untreated sample 
is indicated with one asterisk (p < 0.05).
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These puzzling in vitro results raise the question of what kind of effect PAβN has on P. aeruginosa PAO1 
virulence in vivo. To tackle this issue, the effect of PAβN on P. aeruginosa virulence was assessed in Galleria mel-
lonella, an insect model of infection that well correlates with murine acute infection models28. We firstly aimed 
at validating the infection model by testing the virulence of the efflux-deficient mutant PAO1-KP Δefflux com-
pared to its isogenic wild type strain PAO1-KP. The survival rate of G. mellonella larvae 24 h after the challenge 
with the tested P. aeruginosa strains is shown in Fig. 5A. Nearly all larvae infected with wild type P. aeruginosa 
(PAO1-KP) were killed at the maximum infective dose tested (ca. 45 colony forming units or CFU/larva), and 
larvae survival increased as a function of decreasing infective dose. Conversely, >50% of larvae challenged with 
the efflux-deficient mutant PAO1-KP Δefflux survived also at the maximum infective dose tested. The differences 
between the wild type and the efflux-deficient mutant survival curves were evident at all infection doses (Fig. 5A). 
To the best of our knowledge, this result is the first demonstration that genetic inactivation of RND efflux pumps 
causes a decrease in P. aeruginosa pathogenic potential in vivo. Interestingly, a PAO1 triple mutant inactivated 
in MexAB-OprM, MexCD-OprJ and MexEF-OprN did not show reduced virulence in the same infection model 
in a previous study46. This observation suggests that the deletion of MexXY-OprM in addition to MexAB-OprM, 
MexCD-OprJ and MexEF-OprN in PAO1-KP Δefflux could be critical to reduce the virulence potential of P. 
aeruginosa in the G. mellonella model of infection. However, this issue should be investigated by using identical 
experimental settings and isogenic mutants generated in the same PAO1 strain.
Since the average weight of G. mellonella larvae was ca. 500 mg, and arbitrarily assuming uniform dispersal 
of injected bacteria and PAβN in 500 µl of internal volume in each larva43, we calculated that to reach 50 µM final 
concentration of PAβN, each larva should be injected with 25 µl of saline containing 1 mM PAβN. As a prelim-
inary control experiment, we verified that the injection of 25 µl of saline containing 1 mM PAβN did not affect 
Figure 4. Effect of PAβN on P. aeruginosa motility. (A) P. aeruginosa swimming (white bars) and twitching 
(grey bars) motility in the absence or in the presence of PAßN at the concentrations indicated below the 
histogram. The average diameter of five independent experiments is reported with SD; statistical significance 
with respect to the untreated control sample is indicated with one asterisk (p < 0.05). (B) Images of P. 
aeruginosa swarming plates supplemented with the indicated concentrations of PAßN. (C) Images of P. 
aeruginosa PAO1-KP and PAO1-KP ∆efflux swimming, twitching and swarming plates. For the swarming 
assay, images of the entire plates are reported, while for swimming and twitching assays, magnification of the 
halos are shown. Twitching halos were stained with crystal violet. One representative experiment out of three 
independent replicates is shown for (B) and (C).
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the survival of uninfected larvae (data not shown). Then, G. mellonella larvae were inoculated with P. aeruginosa 
PAO1-KP in the absence or in the presence of PAβN. Results shown in Fig. 5A demonstrate that PAβN was 
able to protect G. mellonella larvae from P. aeruginosa PAO1-KP infection. Interestingly, the survival plot of 
the larvae infected with PAO1-KP and treated with PAβN was slightly lower than that of the untreated larvae 
infected with the efflux-deficient mutant PAO1-KP ∆efflux, but was higher than the untreated control infected 
with wild type PAO1-KP, supporting the hypothesis that PAβN-mediated inhibition of RND efflux pumps is the 
cause of virulence attenuation. Also in this case, it was not possible to directly verify this hypothesis by testing 
the effect of PAβN on PAO1-KP ∆efflux infectivity in G. mellonella due to the toxicity exerted by PAβN on this 
mutant strain19–22. Notably, PAβN exerted a similar protective effect when the larvae were challenged with the P. 
aeruginosa PAO1 strain routinely used in our laboratory (data not shown). Overall, these results strongly suggest 
that the PAβN-mediated inhibition of RND efflux pumps decreases P. aeruginosa PAO1 pathogenicity in G. mel-
lonella, despite the increase in 3OC12-HSL and pyocyanin levels observed in vitro in response to PAβN.
Figure 5. Effect of PAβN on P. aeruginosa virulence in G. mellonella larvae. Viability of G. mellonella larvae 
24 h after injection with the indicated amount of bacteria. Larvae were injected with: (A) The P. aeruginosa 
strains PAO-KP wild type (circles), PAO-KP wild type in the presence of PAßN at ca. 50 µM final concentration 
(diamonds), or PAO1-KP Δefflux (triangles); (B–F) The indicated P. aeruginosa CF isolates in the absence (circles) 
or in the presence of PAßN at ca. 50 µM final concentration (diamonds). Mean values from three independent 
experiments, each performed on at least 30 larvae, are reported with SD; statistical significance with respect to the 
larvae challenged with the indicated strains in the absence of PAßN is indicated with one asterisk (p < 0.05).
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Effect of PAβN on P. aeruginosa cystic fibrosis isolates. The previous observation that PAβN treat-
ment inhibited 3OC12-HSL and pyocyanin production in P. aeruginosa clinical strains21 and our results show-
ing that this EPI has an opposite effect in the reference laboratory strains PAO1 and PAO1-KP suggest that 
virulence-related phenotypes could be variably affected by PAβN, depending on the test strain.
In order to verify this hypothesis, we measured the effect of 27 µM PAβN treatment on 3OC12-HSL and pyo-
cyanin production, as well as swarming motility, in eleven P. aeruginosa clinical strains isolated from the lungs of 
cystic fibrosis (CF) patients47. The growth curve of all tested strains was not affected by PAβN treatment (data not 
shown). Interestingly, among the seven isolates producing 3OC12-HSL, PAβN increased this phenotype in one 
strain (i.e. KK72), had no effect in two strains (i.e. AA2 and KK71), while inhibited the production of this signal 
molecule in the remaining strains, though to different extents (Table 3). Out of four CF isolates that produced 
detectable amounts of pyocyanin, two responded to PAβN by reducing and two by increasing pyocyanin produc-
tion (Table 3). Finally, only five CF isolates showed swarming motility in the absence of PAβN, and this phenotype 
was abrogated upon PAβN treatment in all of them (Table 3).
It appears therefore that PAβN has variable effects on QS signal and pyocyanin production, which are 
strain-dependent. This is in agreement with the previous study21, showing that PAβN inhibited to a differ-
ent extent 3OC12-HSL and C4-HSL levels in two isolates from urinary tract infections, while C4-HSL pro-
duction was not inhibited in two isolates from wound infections. The extent of PAβN-mediated inhibition 
on all the tested virulence-related phenotypes varied significantly among the four clinical isolates previously 
analysed21. In contrast, swarming motility was invariably inhibited in all swarming-proficient CF isolates 
(Table 3). Moreover, for the majority of isolates, no correlation was observed between production/inhibition 
of the 3OC12-HSL signal molecule and the effect of PAβN on pyocyanin levels or swarming motility (Table 3), 
supporting our hypothesis that the effect of PAβN on pyocyanin production is exerted via QS-independent 
pathway(s).
The anti-virulence activity of PAβN against CF clinical isolates was further investigated in G. mellonella lar-
vae in the presence and in the absence of 50 µM PAβN. The CF isolates AA2, AA44, KK2, KK72, and TR1 were 
selected based on their different pattern of virulence phenotypes and sensitivity to PAβN (Table 3). Since the CF 
isolates showed different pathogenicity in the G. mellonella larvae, the optimal range of injected bacteria to be 
used in the infection was preliminarily assessed (data not shown). As shown in Fig. 5C, D and E, PAβN signifi-
cantly increased the survival of G. mellonella larvae challenged with the strains AA44, KK2 and KK72 at all the 
tested infective doses. Conversely, protection from AA2 infection was observed only for low doses of injected 
bacteria (<20 bacteria per larva; Fig. 5B), and poor protection effect was observed when G. mellonella larvae 
where challenged with the TR66 isolate (Fig. 5F).
Overall, PAβN exerted a general protective effect on G. mellonella larvae against P. aeruginosa CF isolates 
(Fig. 5B–F), irrespective of its positive or negative influence on 3OC12-HSL and pyocyanin production (Table S3).
Conclusions
Efflux pumps inhibition is a viable strategy to overcome the problem of antibiotic resistance. Both academic and 
industrial research is currently directed to the development of efflux inhibitors, and the interest in RND efflux 
pump inhibitors as antibiotic adjuvants is steadily increasing over the years2, 5–7. Moreover, the notion that RND 
efflux pumps could play a role in bacterial infection is emerging8, 9, implying that certain EPIs could also be 
endowed with anti-virulence properties. Nevertheless, EPIs are usually considered only for their properties as 
antibiotic adjuvants, while their anti-virulence potential is seldom taken into account.
Here we demonstrate in a simple infection model that RND efflux pumps contribute to the establishment of 
P. aeruginosa PAO1 infection and, accordingly, that the EPI PAβN is able to reduce pathogenicity. In PAO1, the 
protective effect exerted by PAβN in vivo well correlates with in vitro suppression of some virulence-related phe-
notypes and repression of key virulence-related genes.
Straina 3OC12-HSLb Pyocyaninb Swarming motilityb
AA2 102% 86% <10%
AA11 NP 125% NS
AA12 24% 73% NS
AA43 NP NP <10%
AA44 59% 142% <10%
KK2 74% NP NS
KK27 81% NP NS
KK71 97% NP NS
KK72 134% NP NS
TR1 NP NP <10%
TR66 NP NP <10%
Table 3. Effects of PAßN treatment on virulence phenotypes in P. aeruginosa clinical isolates. aP. aeruginosa 
strains isolated from cystic fibrosis patients47. bPercentage of 3OC12-HSL levels, pyocyanin production or 
swarming motility in the presence of 27 µM PAßN with respect to the untreated control. The average of at least 
three independent experiments is reported; SD ≤ 10%. NP, non producer strain; NS, non swarmer strain.
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Although this study was not aimed at investigating the mechanistic link between RND efflux pumps and vir-
ulence, our findings provide relevant hints for future research. The transcriptomic analysis showed that the effect 
of PAβN on P. aeruginosa PAO1 physiology is specific, since it affects particular groups of genes, mainly related 
to iron and phosphate acquisition, as well as nitrogen metabolism. It is particularly relevant that PAβN inhibits 
the transcription of global regulators that are crucial for the establishment of a productive infection, such as the 
sigma factor gene pvdS and the response regulator gene phoB, controlling the regulons responding to iron and 
phosphate starvation, respectively48, 49.
It should be noticed that PAβN may also destabilize the outer membrane of Gram-negative bacteria, in addi-
tion to act as a nonspecific RND efflux pump inhibitor19, 22, 33. However, the majority of studies agree that the 
membrane-destabilizing activity of this molecule is only relevant in strains unable to extrude PAβN (i.e. mutants 
lacking RND efflux pumps), and that PAβN mainly acts as an efflux inhibitor in efflux pump-proficient isolates19, 33. 
Here, PAβN had no effect on the growth rate of P. aeruginosa at concentrations up to 50 µM (Fig. S1), showing 
that in our experimental setting PAβN does not have growth-limiting effects. Most of the transcriptional and 
phenotypic effects observed in this study are controlled by PAβN also in the presence of the membrane stabilizing 
ion Mg2+, and are mimicked by deletion of multiple efflux pumps in the PAO1-KP ∆efflux mutant, strongly sug-
gesting that, in our experimental setting, PAβN mainly acts as an efflux pump inhibitor.
By combining the response of clinical P. aeruginosa isolates to PAβN in vitro (Table 3) and in vivo (Fig. 5), no 
correlation could be established between the effect of this EPI on some virulence phenotypes (i.e. 3OC12-HSL and 
pyocyanin production, swarming motility) and the outcome of G. mellonella infection. This evidence suggests 
either that the protective effect of PAβN in vivo occurs through inhibition of virulence-related trait(s) not investi-
gated in this study, or that the specific virulence factors affected by PAβN may be strain-specific.
Although the number of strains and virulence-related phenotypes tested here and in the previous study21 is 
not sufficient to drive a definitive conclusion, the strain-dependent response to PAβN is an issue that deserves to 
be taken into consideration when testing the anti-virulence properties of any EPI. Unfortunately, PAβN is toxic 
for humans, hindering future therapeutic application and discouraging further studies aimed at characterizing 
the effect of this specific EPI on a wider panel of P. aeruginosa clinical strains. Actually, toxicity toward human 
cells is one of the major obstacle for microbial EPI implementation, and more efforts directed at specifically 
inhibiting efflux pumps operating only in prokaryotes are required. However, the search for new EPI candidates 
with improved pharmacological properties with respect to PAβN is in progress, as testified by the many research 
articles and thoughtful reviews published on this topic2, 5–7.
In conclusion, this study shows that RND efflux pump inhibition has an impact on bacterial virulence in 
vivo, and highlights that any new EPI should be tested not only for its ability to increase the inhibitory activity of 
antibiotics, but also for its anti-virulence effect. Given the strain-dependent response of P. aeruginosa to PAβN, 
anti-virulence properties should be tested on different virulence traits and on large panels of P. aeruginosa isolates 
from different types of infection.
Materials and Methods
Bacterial strains, growth conditions and chemicals. P. aeruginosa strains used in this study are 
listed in Table S2. All strains were routinely grown in Lysogeny Broth (LB)50 supplemented with 50 mM 
3-(N-morpholino)propanesulfonic acid (MOPS), pH 7.0. PAβN (Sigma-Aldrich) was suspended in dimethyl 
sulfoxide (DMSO) at a 10 mM final concentration.
Measurements of promoter activity and phenotypic assays. P. aeruginosa PAO1 strains carrying 
the PphzA1::luxCDABE or PphzA2::luxCDABE transcriptional fusions41 were grown at 37 °C for 10 h in LB or 
in LB supplemented with 27 µM PAβN, 1 mM MgSO4 or 27 µM PAβN plus 1 mM MgSO4. Bioluminescence was 
determined in the resulting cultures as a function of cell density using an automated luminometer-spectrometer 
(Tecan Spark 10M), as previously described41.
Levels of QS signal molecules in P. aeruginosa PAO1, PAO1-KP and PAO1-KP ∆efflux culture supernatants 
were determined during bacterial growth in LB supplemented with different PAβN concentrations and/or 1 mM 
MgSO4, by using the reporter strains specific for 3OC12-HSL, C4-HSL and HHQ/PQS43, 51, 52.
Pyocyanin was extracted with 3 ml of chloroform from 5 ml of cell-free supernatants of P. aeruginosa PAO1, 
PAO1-KP and PAO1-KP ∆efflux cultures grown at 37 °C for 10 h in LB supplemented with different PAβN con-
centrations and/or 1 mM MgSO4, and then re-extracted into 1 ml of 0.2 N HCl. The A520 of the resulting solution 
was measured to determine pyocyanin level43, 44. Proteases and elastase activities were determined in 100 µl of the 
same cell-free supernatants by the azocasein and elastin-Congo red hydrolysis assays, respectively43, 44.
Swimming, swarming and twitching motilities were assessed as previously described43, 44.
Transcriptomic analysis. P. aeruginosa PAOI was inoculated at an A600 of 0.01 into 20 ml of LB with or 
without 27 μM PAβN. The cultures were grown at 37 °C with shaking until they reached an A600 of 2.5, and then 
1 ml of cells was harvested by centrifugation. RNA extraction, retro-transcription and high-density oligonucleo-
tides microarrays transcriptome analysis were performed and analysed as previously described44, 52. RNA integrity 
was monitored by agarose gel electrophoresis, and the absence of contaminating chromosomal DNA was verified 
by PCR with primers pairs FWpqsB-RVpqsB and FW16SRT-RV16SRT (Table S3).
Processing of the P. aeruginosa PAO1 Affimetrix GeneChip® and statistical analysis of the dataset were per-
formed at Lausanne Genomic Technologies Facility, Center for Integrative Genomics, University of Lausanne, 
Switzerland. For each condition, two different pools of RNA were compared (biological duplicate), each contain-
ing RNAs from three independent extractions (technical triplicate). Fold changes >2.0 with a p-value < 0.05 were 
considered as statistically significant.
www.nature.com/scientificreports/
1 2SCIentIFIC REPORTS | 7: 11392  | DOI:10.1038/s41598-017-11892-9
qRT-PCR analyses. Novel P. aeruginosa PAO1 cultures were prepared specifically for qRT-PCR analysis. 
Growth conditions, and sampling for RNA extraction were the same used for the microarray experiments described 
above. When required, LB was also supplemented with 1 mM MgSO4. The same setting were used also for qRT-PCR 
analysis performed in PAO-KP and PAO1-KP ∆efflux. cDNA synthesis was performed from 1 µg of total purified 
RNA by using random hexamer primers and the iScript Reverse Transcription Supermix for RT-qPCR kit (BioRad).
qRT-PCR reactions were performed using the iTaq™ Universal SYBR® Green Supermix (BioRad) and 
primers listed in Table S3, which were designed using the Primer-Blast software (www.ncbi.nlm.nih.gov/tools/
primer-blast). The reaction involved incubation at 95 °C for 1 min and 40 cycles of amplification at 95 °C for 10 s 
and 60 °C for 45 s. The 16 S ribosomal RNA was used as the internal control to calculate the relative fold change 
in gene expression by the 2−∆∆Ct method53. The analysis was performed in duplicate on three technical replicates.
Galleria mellonella killing assay. The G. mellonella killing assay was performed as previously described43, 
with minor modifications. Briefly, G. mellonella caterpillars in the final instar larval stage (average weight, 
480 ± 70 mg) were infected with 25 µl of bacterial cell suspensions in saline containing or not 1 mM PAβN. 
Although P. aeruginosa cells were incubated in the presence of PAβN for less than 15 min before injection, pre-
liminary assays showed that 1 mM PAβN treatment in vitro (for up to 1 h) does not significantly affect P. aerugi-
nosa cell viability (data not shown). One hundred-µl aliquots of the same suspensions were plated on LB agar to 
determine the number of viable cells (CFU) injected in the larvae. Larvae were incubated at 30 °C in Petri dishes 
(ten larvae per dish) and monitored over four days. Larvae were considered dead when they did not respond to 
gentle prodding. At least 30 larvae were inoculated per condition, in three independent experiments.
Statistical analysis. Statistical significance was determined by calculating the p-values using the two-tailed 
Student-t test for unpaired data sets; differences with a p-value ≤ 0.05 are considered as statistically significant.
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